CEACAM5 and cancer: Expanding to women's health, Dosnon et al. introduced MenstruAI, an in-pad diagnostic platform for multiplexed biomarker detection in menstrual blood (Fig. 5F).236 The multilayered microfluidic architecture incorporates plasma filtration and lateral flow immunoassay zones to detect markers such as C-reactive protein (CRP), carcinoembryonic antigen (CEA), and CA-125—relevant to inflammation, cancer, and endometriosis, respectively.